Psychosocial Aspects of Multiple Endocrine Neoplasia (MEN) Syndromes

Multiple Endocrine Neoplasia Clinical Trial

Official title:

Psychosocial Aspects of Multiple Endocrine Neoplasia (MEN) Syndromes

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00501449
• Other study ID #: 2006-0783
• Status: Completed
• Start date: May 2007
• Est. completion date: September 22, 2020

Study information

• Verified date: November 2020
• Source: M.D. Anderson Cancer Center
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

The specific aims of the study include:

1. Profile the demographic, health-related, psychosocial and behavioral characteristics of adults with MEN1 or MEN2.

2. Evaluate MEN-specific distress as well as adherence to surveillance regimens among adults with MEN1 or MEN2, and identify associated with those outcomes.

Description:

The proposed cross-sectional study is intended to obtain information regarding current surveillance behaviors and other psychosocial outcomes among persons affected by the multiple endocrine neoplasia (MEN) 1 or MEN2, which are inherited conditions.

Study participants will include patients who have been seen previously at MDACC for evaluation of MEN1 or MEN2. Because this is the first time investigators are contacting these patients to invite them to participate in psychosocial research, the proposed study also will help determine the feasibility of conducting similar studies in the future.

Investigators anticipate that data gathered from this study will enhance existing knowledge about the psychological and behavioral aspects of the MEN syndromes, and will inform future research efforts directed toward this understudied population.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 133
• Est. completion date: September 22, 2020
• Est. primary completion date: September 22, 2020
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

1. Adults age 18 years or older, with a clinical or genetic diagnosis of MEN1 or MEN2

2. Spouse, Significant Other, or Family Member who is at least 18 years of age and who is related to an individual who is a patient at MDACC and who has been diagnosed with MEN1.

3. Ability to read and write English

Exclusion Criteria:

1) Inability to be contacted via mail (i.e., no contact information on record, incorrect address)

Related Conditions & MeSH terms

• Endocrine Gland Neoplasms
• Multiple Endocrine Neoplasia
• Neoplasms

Intervention

Behavioral:
• Questionnaire
Mailed packets including cover letter describing purpose of study, study questionnaire, and return envelope.

Locations

Country	Name	City	State
United States	University of Texas MD Anderson Cancer Center	Houston	Texas

Sponsors (1)

Lead Sponsor	Collaborator
M.D. Anderson Cancer Center

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Profile the demographic, health-related, psychosocial and behavioral characteristics of adults with MEN1 or MEN2.		3 Years

External Links

•   University of Texas MD Anderson Cancer Center Website